On Wednesday, November 2nd, Dr. Smith's abstract regarding alpha-synuclein seed-amplification was presented at the NEALS convention in Clearwater, Florida.
The presentation was given by one of the authors, Dr. Robert Bowser and the poster that was presented is below.
The FDA is granting the Biogen/Ionis ALS therapy drug tofersen, specific to SOD1 ALS, priority review an should have a decision by January 25th, 2023. This review is sped up to 6 months, compared to a 10 month review.
For more information regarding the priority review and tofersen, check out the press release: https://seekingalpha.com/news/3860495-biogenionis-als-therapy-tofersen-gets-fda-priority-review?source=apple_news&utm_medium=referral
The results from the Phase 3 VALOR Trial and Open-Label Extension were presented at the 20th meeting of the European Network for the Cure of Amyotrophic Lateral Sclerosis (ENCALS) in Edinburgh, Scotland. The presentation slides can be found here.
The data shows that Tofersen use is associated with clinically meaningful benefits in people with SOD1 ALS.